Arcellx (ACLX)
(Delayed Data from NSDQ)
$65.92 USD
+2.57 (4.06%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $65.89 -0.03 (-0.05%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Arcellx, Inc. (ACLX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$77.73 | $87.00 | $52.00 | 22.70% |
Price Target
Based on short-term price targets offered by 15 analysts, the average price target for Arcellx, Inc. comes to $77.73. The forecasts range from a low of $52.00 to a high of $87.00. The average price target represents an increase of 22.7% from the last closing price of $63.35.
Analyst Price Targets (15)
Broker Rating
Arcellx, Inc. currently has an average brokerage recommendation (ABR) of 1.06 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 17 brokerage firms. The current ABR compares to an ABR of 1.06 a month ago based on 17 recommendations.
Of the 17 recommendations deriving the current ABR, 16 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 94.12% and 5.88% of all recommendations. A month ago, Strong Buy made up 94.12%, while Buy represented 5.88%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 16 | 16 | 16 | 15 | 14 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.06 | 1.06 | 1.06 | 1.06 | 1.07 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/18/2024 | Truist Securities | Asthika S Goonewardene | Strong Buy | Strong Buy |
6/17/2024 | SVB Securities | Daina M Graybosch | Strong Buy | Strong Buy |
5/31/2024 | Piper Sandler | Biren Amin | Not Available | Strong Buy |
5/15/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/13/2024 | Evercore Partners | Cory Kasimov | Not Available | Strong Buy |
5/9/2024 | William Blair | Sami Corwin | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Tyler Van Buren | Strong Buy | Strong Buy |
3/18/2024 | Needham & Company | Gil J Blum | Moderate Buy | Moderate Buy |
3/15/2024 | Guggenheim Securities | Kelsey Goodwin | Strong Buy | Strong Buy |
2/29/2024 | H.C. Wainwright & Co. | Emily Bodnar | Strong Buy | Strong Buy |
2/29/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
2/29/2024 | Scotiabank | George Farmer | Strong Buy | Strong Buy |
2/29/2024 | Canaccord Genuity | John L Newman | Strong Buy | Strong Buy |
2/29/2024 | Robert W. Baird & Co. | Jack K Allen | Strong Buy | Strong Buy |
10/17/2023 | UBS | Ashwani Verma | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.06 |
ABR (Last week) | 1.06 |
# of Recs in ABR | 17 |
Average Target Price | $77.73 |
LT Growth Rate | 27.30% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 83 of 252 |
Current Quarter EPS Est: | -0.54 |